ANIP — ANI PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1023024 ·
Last close
$69.99
Market Cap
$1.59B
52W High
$87.76
52W Low
$67.14
ADV30
446,449
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 290,777,000 179,246,000 51,835,000 35,149,000 1,567,661,000 420,758,000 930,548,000
Jun 2026 266,044,000 165,886,000 39,838,000 24,711,000 1,494,112,000 360,212,000 896,900,000
Mar 2026 237,462,000 143,880,000 38,706,000 29,492,000 1,421,970,000 311,176,000 859,670,000
Dec 2025 247,060,000 146,791,000 29,127,000 27,490,000 1,440,377,000 285,585,000 899,653,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$229,197,000
Investing CF
$-29,283,000
Financing CF
$-40,728,000
CapEx
$-29,283,000
Dividends Paid
$0
Buybacks
$-29,758,000
EPS Diluted TTM
$5.02
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$66,253,000
Inventory
$136,411,000
Receivables
$304,450,000
ST Investments
$15,590,000
EBIT TTM
$172,710,000
Pretax Income TTM
$157,838,000
Interest Exp TTM
$14,872,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,041,342,976
EBITDA
$235,330,000
Free Cash Flow
$184,053,504
Enterprise Value
$1,608,332,416
Total Cash
$436,966,016
Total Debt
$617,356,992
Shares Out
22,718,931
Trailing EPS
$5.03
Book Value
$29.84
ROE
20.4%
ROA
6.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 883,366,000 81,230,000 78,337,000 1,440,377,000 899,653,000 540,724,000 185,225,000
Dec 2024 614,376,000 2,218,000 -18,522,000 1,284,469,000 855,939,000 428,530,000 64,017,000
Dec 2023 486,816,000 49,529,000 18,779,000 904,422,000 446,823,000 457,599,000 118,959,000
Dec 2022 316,385,000 -25,734,000 -47,896,000 760,087,000 421,547,000 338,540,000 -31,203,000

TTM Snapshot

Revenues TTM
$978,379,000
NetIncome TTM
$108,310,000
OpCashFlow TTM
—
Assets (Latest)
$1,494,112,000
Forward EPS
$10.13

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $110.00 · spot: $71.47 · call volume: 14 · put volume: 39
Expected Move to 2027-01-15: ±$8.45 (11.82%) — implied range $63.02 – $79.92 · ATM straddle on $70.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KLRA Kailera Therapeutics, Inc. $1.58B $12.20 —
SRPT Sarepta Therapeutics, Inc. $1.58B $14.77 —
NRIX Nurix Therapeutics, Inc. $1.56B $14.24 —
PGEN PRECIGEN, INC. $1.54B $4.29 —
ADRX ADARx Pharmaceuticals, Inc. $1.53B $13.82 —

News headlines (Yahoo Finance, 1h cache)

Did Earnings Beat Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
2026-11-12 00:23 · Yahoo
ANIP Q3 2026 deep dive: rare disease expansion and Cortrophin bottlenecks shape outlook
2026-11-10 10:05 · Yahoo
Is ANI Pharmaceuticals (ANIP) A Bargain After Its $560m Deal?
2026-11-08 10:13 · Yahoo
ANI Pharmaceuticals (ANIP) Offers $560 Million For Rare Disease Expansion
2026-11-08 09:12 · Yahoo
Should ANI Pharmaceuticals (ANIP) Look Undervalued As Results Land And Revenue Guidance Narrows?
2026-11-08 08:09 · Yahoo
ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Offset ...
2026-11-06 01:17 · Yahoo
ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript
2026-11-05 20:09 · Yahoo
ANI Pharmaceuticals Q3 Earnings Call Highlights
2026-11-05 18:15 · Yahoo
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
2026-11-05 13:30 · Yahoo
ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026
2026-11-05 12:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.